GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enliven Therapeutics Inc (NAS:ELVN) » Definitions » EV-to-EBIT

Enliven Therapeutics (Enliven Therapeutics) EV-to-EBIT : -8.67 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Enliven Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Enliven Therapeutics's Enterprise Value is $806.98 Mil. Enliven Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-93.10 Mil. Therefore, Enliven Therapeutics's EV-to-EBIT for today is -8.67.

The historical rank and industry rank for Enliven Therapeutics's EV-to-EBIT or its related term are showing as below:

ELVN' s EV-to-EBIT Range Over the Past 10 Years
Min: -110.78   Med: 0   Max: 0
Current: -8.67

ELVN's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Biotechnology industry
Industry Median: 9.84 vs ELVN: -8.67

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Enliven Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $501.29 Mil. Enliven Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-93.10 Mil. Enliven Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -18.57%.


Enliven Therapeutics EV-to-EBIT Historical Data

The historical data trend for Enliven Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enliven Therapeutics EV-to-EBIT Chart

Enliven Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -3.82

Enliven Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.08 -9.75 -4.22 -3.82 -

Competitive Comparison of Enliven Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Enliven Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enliven Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enliven Therapeutics's EV-to-EBIT falls into.



Enliven Therapeutics EV-to-EBIT Calculation

Enliven Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=806.983/-93.098
=-8.67

Enliven Therapeutics's current Enterprise Value is $806.98 Mil.
Enliven Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enliven Therapeutics  (NAS:ELVN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Enliven Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-93.098/501.285432
=-18.57 %

Enliven Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $501.29 Mil.
Enliven Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-93.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enliven Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Enliven Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Enliven Therapeutics (Enliven Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
Anish Patel officer: Chief Operating Officer C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Benjamin Hohl officer: Chief Financial Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Joseph P Lyssikatos director, officer: Chief Scientific Officer 6200 LOOKOUT ROAD, BOULDER CO 80301
Samuel Kintz director, officer: President and CEO ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301
Richard A. Heyman director 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Rishi Gupta director, 10 percent owner C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Andrew J. Schwab director C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Helen Louise Collins director TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jake Bauer director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107

Enliven Therapeutics (Enliven Therapeutics) Headlines